In adverse event reports, vosoritide was linked to a joint deformity signal with ROR=125.78.
In plain wordsIn adverse event reports, vosoritide was linked to a joint deformity reporting signal.
- Peptide
- Vosoritide
- Outcome
- IncreaseJoint deformity reporting signal
- Study
n: not reported in source
- Outcome group
- Adverse events · Musculoskeletal
- Studied dose
- Dose not stated
Measurements
- Reporting odds ratio for joint deformity
- 125.78 ratio
- vosoritide, FAERS reports
Source sentences
For joint deformity, alendronic acid, valproic acid, and somatropin showed strong associations, and nine novel signals were identified (e.g. vosoritide, ROR=125.78).
2 context sentences(design, population, supporting numbers)
Adverse event reports from the FDA Adverse Event Reporting System (FAERS; Q1 2004-Q2 2025) were analysed.
Disproportionality analyses (ROR) with false discovery rate correction were performed overall and by sex.